A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GMTs / geometric mean titers

[Related PubMed/MEDLINE]
Total Number of Papers: 367
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GMTs  (>> Co-occurring Abbreviation)
Long Form:   geometric mean titers
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus. HIV, HPV, PRISMA
2019 A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. CI, ELISA, EU, HPV, SAEs, VLP
2019 An adjuvant compound that enhances immunogenicity at fractional doses of the Sabin-inactivated poliovirus vaccine (sIPV) with a long duration of protection in a rat model. OPV, sIPV
2019 Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. ---
2019 Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial. OPA, QIV
2019 Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013-2014 Through 2015-2016. GMFR, LAIV
2019 Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population. HAI, NAI
2019 Heterotypic Neuraminidase Antibodies Against Different A(H1N1) Strains are Elicited after Seasonal Influenza Vaccination. ELLA, NA
2019 Immunity status against poliomyelitis in young migrants: a seroprevalence study. PV1, PV2, PV3
10  2019 Immunogenicity and safety of 3 formulations of a respiratory syncytial virus candidate vaccine in non-pregnant women: a phase II, randomized trial. PCA, RSV
11  2019 Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax in healthy adults aged 50 years and older. AEs, ELISPOT, gpELISA, IFN, IL
12  2019 Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh. ELISAs, IgA, LAIV, NPW
13  2019 Immunogenicity of pentavalent rotavirus vaccine in Chinese infants. DTaP, SNAs, tOPV
14  2019 Immunogenicity, Lot Consistency, and Extended Safety of rVSVDeltaG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. ELISA, PFU
15  2019 Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan. AEs, EV-A71, SAEs
16  2019 Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials. CMI, SAEs
17  2019 Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine. 9vHPV, qHPV
18  2019 MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications. AEs, SAEs
19  2019 Persistence and gender differences in protection against severe fever with thrombocytopaenia syndrome virus with natural infection: a 4-year follow-up and mathematical prediction study. CI, SFTS, SFTSV
20  2019 Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. OPA
21  2019 Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination. bHPV, HPV, qHPV
22  2019 Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. GMCs, OPA, Tdap
23  2019 Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan. cIPV, DTaP-sIPV, IPV, NESVPD, OPV
24  2019 Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. GMCs, IgG, OPA
25  2019 Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. GMCs, GMFRs, IgG, OPA
26  2019 Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. CI, NAbs, RSV
27  2019 Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial. HAI
28  2019 Safety, immunogenicity, and lot-to-lot consistency of live attenuated varicella vaccine in 1-3 years old children: a double-blind, randomized phase III trial. CI, CS, LPS, NATb
29  2019 Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence. NT, TBE, TBEV, TBEvac
30  2018 A cross-sectional seroepidemiology study of EV-D68 in China. AFM, LRTIs, NtAbs, URTIs
31  2018 Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. ---
32  2018 Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial. AEs, OCV
33  2018 Characterization of source plasma from self-identified vaccinated or convalescent donors during the 2009 H1N1 pandemic. HAI
34  2018 Declining responsiveness to influenza vaccination with progression of human pregnancy. ELISA, HAI
35  2018 Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults. hSBA
36  2018 Immune Responses to Twice-Annual Influenza Vaccination in Older Adults in Hong Kong. H3N2
37  2018 Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study. CI, JE-CV
38  2018 Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. TDV
39  2018 Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study. FHA, GMCs, PRN, PT, Tdap
40  2018 Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial. AE, ELISA, MVA, PRNT
41  2018 Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults. YF
42  2018 Immunogenicity of the meningococcal polysaccharide conjugate vaccine in pediatric kidney transplant patients. ---
43  2018 Intranasal administration of inactivated avian influenza virus of H5N1 subtype vaccine-induced systemic immune response in chicken and mice. AIV-H5N1, HI, HIU, INM, NDV
44  2018 Measles immunity at 4.5 years of age following vaccination at 9 and 15-18 months of age among HIV-infected, HIV-exposed-uninfected and HIV-unexposed children. CI, HEU
45  2018 MF59-adjuvanted influenza vaccine (FLUAD) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone): A randomized, multicenter, Phase III pediatric trial in Mexico. AEs, aTIV, TIVs
46  2018 Neutralization and hemagglutination-inhibition antibodies following influenza vaccination of HIV-infected and HIV-uninfected pregnant women. HAI, MN
47  2018 One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study. rV, SAEs
48  2018 Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. CLL, ELISA, OPA
49  2018 Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. GMCs, OPA, PCV
50  2018 Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥50 years of age. GMCs, OPA
51  2018 Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. rSBA
52  2018 Safety and immunogenicity of inactivated monovalent influenza A/H1N1 vaccine candidate manufactured in Vietnam. HAI, IVAC, MN
53  2018 Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5years does not affect the immunogenicity and safety in the Japanese elderly. GMCs, IgG, OPA
54  2017 Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults. MOPA, OPA
55  2017 Immunity against influenza A(H1N1) infections is determined by age at the time of initial strain circulation. HI
56  2017 Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial. HI, MGI, MN, SCR, SPR, VRR
57  2017 Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. AEs, HI, QIV, SCRs, TIVs, Vic, Yam
58  2017 Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. 9vHPV
59  2017 Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4y after vaccination. ---
60  2017 Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59. HI, ITIV, PA
61  2017 Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial. MenC, PS
62  2017 Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Ad5-EBOV
63  2017 SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. cLIA, FBI, OPA, rmClfA, rMntC
64  2017 Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults. aP, FHA, PRN, TdaP, Tdap, TdaP
65  2017 Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. PFU, TDV, TDV-2
66  2017 Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: A phase I randomised trial. PFU, ZEBOV
67  2017 Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆. OPA, Tdap
68  2017 The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Ab, AE, nvAE, qHPV, VSRs
69  2017 [An investigation on immunological effect of hepatitis B vaccine amongst adult population in high-labor-export rural regions, under 4 different strategies]. ---
70  2016 A Survey of Serum Bactericidal Antibodies against Neisseria meningitidis Serogroups A, C, W and Y in Adolescents and Adults in the Republic of Korea. CIs, hSBA
71  2016 Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats. D-Ag, i.d, IM, OPV, sIPV, WPV
72  2016 Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates. ADE, DENV, FcgammaR, ISG, mAbs
73  2016 Cerium dioxide nanoparticles increase immunogenicity of the influenza vaccine. FI, HI
74  2016 Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial. ANZCTR, GMC, OPA, Tdap
75  2016 Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. AEs, GMCs, IgG, OPA, SAEs
76  2016 Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial. ---
77  2016 Immunogenicity and safety of different schedules of 2-dose varicella vaccination in China. ---
78  2016 Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine. IMBV
79  2016 Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM. Td
80  2016 Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children. TIV
81  2016 Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus. JE, JEV, SCRs
82  2016 Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. fHbp, MnB
83  2016 Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination. HI, LAIV, MN, VE
84  2016 Rapid immunization effects of a new type of 60mug hepatitis B vaccine compared with traditional 20mug hepatitis B vaccines in adults. ---
85  2016 Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. AEs, GMCs, IgG, OPA
86  2016 Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. AEs, SAEs
87  2016 Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China. GMCs, IPDs, OPA
88  2016 Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea. Tdap
89  2016 Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu. SCRs, SPRs
90  2016 Serum Concentrations of Antibodies against Outer Membrane Protein P6, Protein D, and T- and B-Cell Combined Antigenic Epitopes of Nontypeable Haemophilus influenzae in Children and Adults of Different Ages. Hib, NTHi, OMPs
91  2016 [Seroepidemiological Studies on Pertussis, Diphtheria and Tetanus among Nursing Students Enrolled between 1994 and 2011 in the Kitakyushu District]. FHA, PT
92  2015 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. GMCs, IgG, OPA, SCD
93  2015 Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. ---
94  2015 Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety. CI, MMRV, RCTs
95  2015 Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial. CI, GMFR, IFN-gamma ELISPOT, IM, s.c, VZV
96  2015 Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. HIA
97  2015 Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. CI, cLIA, HPV6, LIA, LTFU, qHPV
98  2015 Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults. MOPA, OPA
99  2015 Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. GMCs, OPA, PCVs
100  2015 Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. HPV